Opinion/decision on a Paediatric investigation plan (PIP): Iscalimab, decision type: , therapeutic area: , PIP number: P/0222/2021

Human medicines European public assessment report (EPAR): Aubagio, teriflunomide, Multiple Sclerosis, Date of authorisation: 26/08/2013, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Glomerulonephritis, IGA, Date of authorisation: 15/07/2022, Revision: 5, Status: Authorised

Meeting summary of the Medicine Shortages (SPOC) Working Party meeting 16 June 2023

Meeting summary of the Medicine Shortages (SPOC) Working Party 24 May 2023

Human medicines European public assessment report (EPAR): Abseamed, epoetin alfa, Anemia;Kidney Failure, Chronic;Cancer, Date of authorisation: 27/08/2007, Date of refusal: 18/06/2009, Revision: 22, Status: Authorised

Q&A: Good clinical practice (GCP)

Human medicines European public assessment report (EPAR): Fingolimod Accord, fingolimod, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 25/06/2020, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Ovaleap, follitropin alfa, Anovulation, Date of authorisation: 27/09/2013, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Azilect, rasagiline, Parkinson Disease, Date of authorisation: 21/02/2005, Revision: 23, Status: Authorised